How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

3 weeks ago
R&D
Coronavirus

BAR­DA of­fers a tiny start­up up to $812M to cre­ate a US-based drug man­u­fac­tur­er — and the CEO comes with a price goug­ing con­tro­ver­sy on his ré­sumé

3 weeks ago
Startups
Deals

Roche’s James Sabry ze­roes in on a new path­way for pro­tein degra­da­tion — and he’s pay­ing $135M cash for a hot tick­et

3 weeks ago
Deals

J&J posts a sol­id round of pos­i­tive ear­ly da­ta for their BC­MA/CD3 bis­pe­cif­ic teclis­tam­ab, high­light­ing block­buster ex­pec­ta­tions

3 weeks ago
R&D

As­traZeneca nabs break­through sta­tus, as $7B ADC races to block­buster sta­tus

3 weeks ago
R&D
Regulatory

Mod­er­na posts a promis­ing snap­shot of hu­man da­ta for a lead­ing Covid-19 vac­cine — and ral­ly makes Bob Langer a bil­lion­aire

3 weeks ago
R&D
Coronavirus

Pfiz­er gene ther­a­py ups lev­els of dy­s­trophin ex­pres­sion in Duchenne tri­al — but an­oth­er safe­ty set­back mars re­sults

4 weeks ago
R&D
Cell/Gene Tx

ADC steams back to vir­tu­al Wall Street — and this time the team scores a $233M IPO haul

4 weeks ago
IPOs

BIO gets a new chief lob­by­ist to face off against the grow­ing ranks of crit­ics in Con­gress

4 weeks ago
People
Bioregnum

BC­MA ri­val to blue­bird, Bris­tol My­ers files for $100M IPO as the fron­trun­ners stum­ble in a race to the fin­ish line

4 weeks ago
IPOs
R&D

It's Mon­cef Slaoui. Trump ad­min­is­tra­tion set­tles on ex-GSK vac­cines chief as Covid-19 R&D czar — re­ports

4 weeks ago
People
Coronavirus

Al­lo­gene spot­lights their off-the-shelf CAR-T con­tender ‘501 with a snap­shot on CRs and no GVHD

4 weeks ago
R&D

Days af­ter rapid FDA ap­proval, Lil­ly and Blue­print go head-to-head again at AS­CO

4 weeks ago
R&D

Macro­Gen­ics chief Scott Koenig de­tails the up­beat can­cer drug da­ta from 2 pro­grams that drove a big spike in their share price

4 weeks ago
R&D

Am­gen re­searchers con­firm the lack­lus­ter da­ta on the KRAS G12C drug AMG 510 re­port­ed at ES­MO — but they still have a long way to go ex­plor­ing op­tions

4 weeks ago
R&D

Bris­tol My­ers Squibb spells out OS ben­e­fit of Op­di­vo/Yer­voy com­bo plus 'lim­it­ed' chemother­a­py — is it enough to change prac­tice?

4 weeks ago
R&D
Pharma

In race to lead the TIG­IT pack in I/O, Roche de­liv­ers pos­i­tive PhII da­ta — but big ques­tions linger

4 weeks ago
R&D

FDA slams blue­bird and Bris­tol My­ers with a sur­prise RTF on ide-cel, but ex­ecs in­sist they can over­come set­back quick­ly

4 weeks ago
R&D
Regulatory

Vivek Ra­maswamy’s broth­er, Shankar, spins out on his own, launch­ing au­da­cious gene ther­a­py play

4 weeks ago
People
Venture

Covid-19 roundup: The FDA gives Mod­er­na’s Covid-19 team a reg­u­la­to­ry em­brace to go along with the cheers and jeers; BioN­Tech ex­pects first coro­n­avirus da­ta in a mat­ter of weeks

4 weeks ago
Coronavirus

Ex-DARPA chief Regi­na Dugan, for­mer Il­lu­mi­na CEO Jay Flat­ley lead $300M Well­come Trust fund to tack­le glob­al health's Sput­nik mo­ment

4 weeks ago
People

CEPI bets $384M on No­vavax’s Covid-19 vac­cine — cov­er­ing R&D and man­u­fac­tur­ing in the ground­break­ing race to beat the pan­dem­ic

4 weeks ago
R&D
Coronavirus

'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

4 weeks ago
R&D

Blue­bird takes $200M pay­out from Bris­tol My­ers as Covid-19, BLA de­lays force ex­ecs to bring out the bud­get ax

4 weeks ago
Deals
Regulatory
First page Previous page 123456 Next page Last page